Identifying
biomarkers for the early diagnosis of
glioma and elucidating the molecular mechanisms underlying the development of this
cancer are of considerable clinical importance. Recently, studies performing microarray profiling of genes to identify distinct gene signatures reported specific subtypes with predictive and prognostic relevance. Thus, we performed deep sequencing on a total of 26
glioma tissue samples to identify the frequently mutated of oncogenes and
tumor suppressors in
gliomas. A total of 2306 single-nucleotide polymorphisms (SNPs) and 2010 insertion and deletion sites (indels) were found by aligning sequencing information from 26
glioma samples with sequences from the normal human gene database (GRCh37/hg19). GSEA results suggest that an underexpressed gene,
calmodulin binding transcription activator 1 (CAMTA1), participates in the cell proliferation and cell cycle regulation of
glioma cells. Moreover, overexpression of CAMTA1 in
glioma cells notably inhibited cell growth, migration, invasion and cell cycle and enhanced
temozolomide (TMZ)-induced cell apoptosis in
glioma cells, while CAMTA1 overexpression decreased the ITGA5, ITGB1, p-AKT, p-FAK, and Myc
protein levels, suggesting that the signaling pathways of these
proteins might be involved in the cellular functions of CAMTA1 in
glioma. Moreover, overexpression of CAMTA1 attenuated the growth and
tumorigenesis of
glioma in vivo. In summary, we identified high-frequency mutant genes in
glioma and provided an experimental basis for a novel mechanism by which CAMTA1 may serve as a
tumor suppressor in
glioma.